Exact Mass: 426.2253564
Exact Mass Matches: 426.2253564
Found 500 metabolites which its exact mass value is equals to given mass value 426.2253564,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Paliperidone
Paliperidone is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed that paliperidone and risperidone act via similar if not the same pathways. It has been proposed that the drugs therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a dopamine D2 antagonist and 5-HT2A antagonist. Paliperidone is also active as an antagonist at α1 and α2 adrenergic receptors and H1-histaminergic receptors. Paliperidone, a antipsychotic agent, shows efficacy against schizophrenia[1]. Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a dopamine D2 antagonist and 5-HT2A antagonist. Paliperidone is also active as an antagonist at α1 and α2 adrenergic receptors and H1-histaminergic receptors. Paliperidone, a antipsychotic agent, shows efficacy against schizophrenia[1].
Cariprazine
C21H32Cl2N4O (426.19530419999995)
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics Cariprazine is a novel antipsychotic agent candidate that exhibits high affinity for the D3 (Ki=0.085 nM) and D2 (Ki=0.49 nM) receptors, and moderate affinity for the 5-HT1A receptor (Ki=2.6 nM).
Oxatomide
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AE - Piperazine derivatives D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents Oxatomide is a first-generation piperazine H1-antihistamine. D018926 - Anti-Allergic Agents Oxatomide is a potent and orally active dual H1-histamine receptor and P2X7 receptor antagonist with antihistamine and anti-allergic activity. Oxatomide almost completely blocks the ATP-induced current in human P2X7 receptors (IC50 of 0.95 μM). Oxatomide inhibits ATP-induced Ca2+ influx with an IC50 value of 0.43 μM and also inhibits serotonin[1][2].
Cinnzeylanine
Constituent of Cinnamomum zeylanicum (cinnamon) and Cinnamomum cassia (Chinese cinnamon). Cinnzeylanine is found in chinese cinnamon, ceylon cinnamon, and herbs and spices. Cinnzeylanine is found in ceylan cinnamon. Cinnzeylanine is a constituent of Cinnamomum zeylanicum (cinnamon) and Cinnamomum cassia (Chinese cinnamon)
1-[3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4,5,6-tetrahydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one
Darifenacin
G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists Darifenacin (Enablex, Novartis) is a medication used to treat urinary incontinence. C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D000089162 - Genitourinary Agents > D064804 - Urological Agents Darifenacin(UK88525) is a selective M3 muscarinic receptor antagonist with pKi of 8.9. IC50 value: 8.9 (pKi) [1] Target: M3 receptor in vitro: Darifenacin exerts non-parallel rightward displacement of the agonist curve and also significant depression of the maximum response (+)-cis-Dioxolane produced concentration-dependent contraction of the isolated bladder of rat [1]. Darifenacin produces a concentration dependent increase in R123 (P-gp probe) accumulation in MDCK cells. Darifenacin stimulates ATPase activity in P-gp membrane in a clear concentration dependent response manner with an estimated ED50 value of 1.6 μM. Darifenacin (100 nM) shows a significantly greater permeability for darifenacin in the basolateral to apical direction resulting in an efflux ratio in BBMEC monolayers of approximately 2.6 [2]. in vivo: Darifenacin produces dose-dependent inhibition of amplitude of volume-induced bladder contractions(VIBCAMP), producing 35\% inhibition at dose of 283.3 nmol/kg and maximal inhibition of approximately 50–55\% [1]. Darifenacin (0.1 mg/kg i.v.) reduces bladder afferent activity in both Aδ and C fibers in female Sprague-Dawley rats, the decrease in afferent spikes in C fibers may be more pronounced than that in Aδ fibers [3].
11,13-Dihydrotaraxinic acid glucosyl ester
Constituent of Taraxacum officinale (dandelion). 11,13-Dihydrotaraxinic acid glucosyl ester is found in many foods, some of which are tea, alcoholic beverages, coffee and coffee products, and dandelion. 11,13-Dihydrotaraxinic acid glucosyl ester is found in alcoholic beverages. 11,13-Dihydrotaraxinic acid glucosyl ester is a constituent of Taraxacum officinale (dandelion)
(2,3-Dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl)methanone monomethanesulfonate
C27H26N2O3 (426.19433260000005)
9-Hydroxy-risperidone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)propyl)-4-hydroxy-3-methoxy-alpha-(1-methylethyl)-
C25H34N2O4 (426.25184440000004)
Gemfibrozil 1-O-beta-Glucuronide
(2s)-7-Amino-2-{[(R)-Hydroxy{(1r)-2-Methyl-1-[(3-Phenylpropanoyl)amino]propyl}phosphoryl]methyl}heptanoic Acid
C21H35N2O5P (426.22834700000004)
Dual-release hydrocortisone
C22H38N2O4S (426.25521480000003)
Iloperidone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics Iloperidone (HP 873) is a D2/5-HT2 receptor antagonist. Iloperidone is an atypical antipsychotic for the schizophrenia symptoms[1][2].
MEK inhibitor
Pratosartan
Ripisartan
Teneligliptin
Cichorioside N
Cichorioside n is slightly soluble (in water) and a very weakly acidic compound (based on its pKa). Cichorioside n can be found in endive, which makes cichorioside n a potential biomarker for the consumption of this food product.
Sonchuside E
Methyl 17-(acetyloxy)-11-methoxyyohimban-16-carboxylate #
Broussoflavan A
2,4,6,3,4-Pentahydroxy-3,5-diprenyldihydrochalcone
(5-methyl-3-(morpholinomethyl)-2,3-dihydro-[1,4]oxazino[2,3,4-hi]indol-6-yl)(naphthalen-1-yl)methanone
C27H26N2O3 (426.19433260000005)
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002491 - Central Nervous System Agents > D000700 - Analgesics D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators
(+)-3,4-(6,6-dimethyldihydropyrano)-4,5-[2-(1-hydroxy-1-methylethyl)-dihydrofurano]-2,3-dihydroxydihydrochalcone|bartericin C
3-O-beta-D-glucopyranosyl-3beta,14-dihydroxycostunolide
1,8-dihydroxy-3-(3,7-dimethyl-7-methoxyoct-2-enyloxy)-6-methyl xanthone
7beta-O-beta-glucopyranosyl bombaxone|7beta-O-beta-glucopyranosyl-10beta-hydroxy hibiscone B
3-hydroxymethyl-aspidofractinine-1,3-dicarboxylic acid dimethyl ester|Pleiocarpolin
Hexyl 6-O-(beta-D-glucopyranosyl)-beta-D-glucopyranoside|Hexyl-??-D-glucopyranosyl-(1鈥樏傗垎 6)-??-D-glucopyranoside
1beta-O-((E)-p-methoxycinnamoyl)-6alpha-hydroxypolygodial|1beta-[(E-p-methoxycinnamoyl)oxy]-6alpha-hydroxypolygodial|isodrimanial
(19R)-1-acetyl-17,19-epoxy-10,11-dimethoxy-4-methyl-3,4-seco-cur-20-en-3-one|10,11-dimethoxy-strychnobrasiline|10,11-Dimethoxystrychnobrasilin|10,11-Dimethoxystrychnobrasiline
2,4-Diamino-2,4,6-trideoxygalactose-Benzyl glycoside, di-N-Ac, 3-benzyl
10beta,14-dihydroxy-10(14),11beta(13)-tetrahydro-8,9-didehydro-3-deoxyzaluzanin C-10-O-beta-glucopyranoside
3-O-acetyl-4,5-O-di-(3methylvaleryl)-shikimic acid methyl ester|3-O-acetyl-4,5-O-di-<3methylvaleryl>-shikimic acid methyl ester
1-[3-(6,7-dihydroxy-3,7-dimethyloct-2-enyl)-2,4-dihydroxyphenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one
8beta-hydroxy-4alpha,15-dihydrozaluzanin C-3-O-beta-glucopyranoside
(1R,5R,6R,7S,9R)-6,9alpha-epoxy-9,15-bisabolanolide-5-O-beta-D-glucopyranoside|abiespiroside A
(4S,7R)-7-[(1E,3E,5E,7E)-8-[(2S,5R,6S)-5,6-dihydro-5-hydroxy-3,5,6-trimethyl-2H-pyran-2-yl]nona-1,3,5,7-tetraen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione|wortmannilactone F
(5Z,8Z,11Z,13E,17Z)-2-eicosa-15(S)-hydroxy-5,8,11,13,17-pentaenoylphloroglucinol
10beta-formamido-5-isocyanatokalihinol-A
C22H35ClN2O4 (426.22852200000005)
(3S)-3-hydroxyatractylenolide III 3-O-beta-D-glucopyranoside|(3S)-3-Hydroxyatractylenolide III 3-O-??-D-glucopyranoside|(3S,5R,8R,10R)-3,8-dihydroxyeudesma-4(15),7(11)-diene-8,12-olide 3-O-beta-D-glucopyranoside
cynarascoloside C|isoamberboin 8-O-beta-D-glucopyranoside
7alpha,21-dihydroxy-3-oxo-24,25,26,27-tetranorapotirucall-1,14,20(22)-trien-21,23-olide
4alpha-O-beta-D-glucopyranosyl-15-hydroxyl-5alpha,6betaH-guaiane-10(14),11(13)-dien-12,6alpha-olide
(1R,2S)-1-{[(1S,4aR,5R,8aS)-decahydro-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthalen-1-yl]methoxy}propane-1,2,3-tricarboxylic acid 2-methyl ester|cryptoporic acid N
(2R,3R)-7,4-dihydroxy-6-(3-hydroxy-3-methylbutyl)-8-(3-methylbut-2-en-1-yl)dihydroflavonol
13,17-epoxy-1beta,11beta,12alpha,14beta,15beta-pentahydroxy-2alpha-methoxypicras-3-en-16-one|bruceine M
5-{(E)-2-[2-(1H-indol-5-yl)-1,4-bis(methoxymethyl)cyclohex-3-en-1-yl]ethenyl}-1H-indole|caulindole E
Hexyl beta-sophoroside|Hexyl-??-D-glucopyranosyl-(1鈥樏傗垎 2)-??-D-glucopyranoside
(4-methylpentyl-beta-D-glucopyranosyl-(1->6)-beta-D-glucopyranoside|capsoside B
4-acetoxy-3-hydroxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester
2,4,6,3,4-Pentahydroxy- 3,5-diprenyldihydrochalcone
2,3-epoxy-5beta,6beta,9,10alpha,16alpha-pentahydroxy-7alpha-acetoxygrayanane|craiobiotoxin IV
2-Methylbutanoic acid 3-[2-(3,4-dimethoxyphenyl)-7-methoxybenzofuran-5-yl]propyl ester
fukanedone E|rel-3(S)-(2-hydroxy-4-methoxybenzoyl)-4(R),5(R)-dimethyl-5-[4-methyl-5-(4-methyl-2-furyl)-3(E)-penten-1-yl]tetrahydro-2-furanone
16beta-acetyloxy-14-hydroxy-bufa-5,20,22-trienolide
(5beta,9alpha,10alpha)-7-O-(3alpha-methoxy-8(12)-drimen-11-yl)-scopoletin|driportlandin
alpha,3,4,2,4-Pentahydroxy-5,3-diprenyl-alpha,beta-dihydro-trans-chalcone
2-[6-hydroxy-3,7-dimethylocta-2(E),7-dienyl]-2,3,4,4-tetrahydroxydihydrochalcone
Paliperidone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics CONFIDENCE standard compound; INTERNAL_ID 1568 Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a dopamine D2 antagonist and 5-HT2A antagonist. Paliperidone is also active as an antagonist at α1 and α2 adrenergic receptors and H1-histaminergic receptors. Paliperidone, a antipsychotic agent, shows efficacy against schizophrenia[1]. Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a dopamine D2 antagonist and 5-HT2A antagonist. Paliperidone is also active as an antagonist at α1 and α2 adrenergic receptors and H1-histaminergic receptors. Paliperidone, a antipsychotic agent, shows efficacy against schizophrenia[1].
8-(2,4-dihydroxy-6-pentylphenoxy)-6-hydroxy-3-pentylisochromen-1-one
Perospirone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent Perospirone (SM-9018 free base) is an orally active antagonist of 5-HT2A receptor (Ki=0.6 nM) and dopamine D2 receptor (Ki=1.4 nM), and also a partial agonist of 5-HT1A receptor (Ki=2.9 nM). Perospirone is an atypical antipsychotic agent and has the potential for schizophrenic disease research[1][2].
Ala His Ile Ser
Ala His Leu Ser
Ala His Ser Ile
Ala His Ser Leu
Ala His Thr Val
Ala His Val Thr
Ala Ile His Ser
Ala Ile Ser His
Ala Leu His Ser
Ala Leu Ser His
Ala Ser His Ile
Ala Ser His Leu
Ala Ser Ile His
Ala Ser Leu His
Ala Thr His Val
Ala Thr Val His
Ala Val His Thr
Ala Val Thr His
Asp Pro Pro Val
Asp Pro Val Pro
Asp Val Pro Pro
Phe Phe Gly Gly
C22H26N4O5 (426.19031060000003)
Phe Gly Gly Phe
C22H26N4O5 (426.19031060000003)
Gly Phe Phe Gly
C22H26N4O5 (426.19031060000003)
Gly Phe Gly Phe
C22H26N4O5 (426.19031060000003)
Gly Gly Phe Phe
C22H26N4O5 (426.19031060000003)
Gly His Ile Thr
Gly His Leu Thr
Gly His Thr Ile
Gly His Thr Leu
Gly Ile His Thr
Gly Ile Thr His
Gly Leu His Thr
Gly Leu Thr His
Gly Thr His Ile
Gly Thr His Leu
Gly Thr Ile His
Gly Thr Leu His
His Ala Ile Ser
His Ala Leu Ser
His Ala Ser Ile
His Ala Ser Leu
His Ala Thr Val
His Ala Val Thr
His Gly Ile Thr
His Gly Leu Thr
His Gly Thr Ile
His Gly Thr Leu
His Ile Ala Ser
His Ile Gly Thr
His Ile Ser Ala
His Ile Thr Gly
His Leu Ala Ser
His Leu Gly Thr
His Leu Ser Ala
His Leu Thr Gly
His Ser Ala Ile
His Ser Ala Leu
His Ser Ile Ala
His Ser Leu Ala
His Thr Ala Val
His Thr Gly Ile
His Thr Gly Leu
His Thr Ile Gly
His Thr Leu Gly
His Thr Val Ala
His Val Ala Thr
His Val Thr Ala
Ile Ala His Ser
Ile Ala Ser His
Ile Gly His Thr
Ile Gly Thr His
Ile His Ala Ser
Ile His Gly Thr
Ile His Ser Ala
Ile His Thr Gly
Ile Pro Pro Thr
Ile Pro Thr Pro
Ile Ser Ala His
Ile Ser His Ala
Ile Thr Gly His
Ile Thr His Gly
Ile Thr Pro Pro
Leu Ala His Ser
Leu Ala Ser His
Leu Gly His Thr
Leu Gly Thr His
Leu His Ala Ser
Leu His Gly Thr
Leu His Ser Ala
Leu His Thr Gly
Leu Pro Pro Thr
Leu Pro Thr Pro
Leu Ser Ala His
Leu Ser His Ala
Leu Thr Gly His
Leu Thr His Gly
Leu Thr Pro Pro
Pro Asp Pro Val
Pro Asp Val Pro
Pro Ile Pro Thr
Pro Ile Thr Pro
Pro Leu Pro Thr
Pro Leu Thr Pro
Pro Pro Asp Val
Pro Pro Ile Thr
Pro Pro Leu Thr
Pro Pro Thr Ile
Pro Pro Thr Leu
Pro Pro Val Asp
Pro Thr Ile Pro
Pro Thr Leu Pro
Pro Thr Pro Ile
Pro Thr Pro Leu
Pro Val Asp Pro
Pro Val Pro Asp
Ser Ala His Ile
Ser Ala His Leu
Ser Ala Ile His
Ser Ala Leu His
Ser His Ala Ile
Ser His Ala Leu
Ser His Ile Ala
Ser His Leu Ala
Ser Ile Ala His
Ser Ile His Ala
Ser Leu Ala His
Ser Leu His Ala
Thr Ala His Val
Thr Ala Val His
Thr Gly His Ile
Thr Gly His Leu
Thr Gly Ile His
Thr Gly Leu His
Thr His Ala Val
Thr His Gly Ile
Thr His Gly Leu
Thr His Ile Gly
Thr His Leu Gly
Thr His Val Ala
Thr Ile Gly His
Thr Ile His Gly
Thr Ile Pro Pro
Thr Leu Gly His
Thr Leu His Gly
Thr Leu Pro Pro
Thr Pro Ile Pro
Thr Pro Leu Pro
Thr Pro Pro Ile
Thr Pro Pro Leu
Thr Val Ala His
Thr Val His Ala
Val Ala His Thr
Val Ala Thr His
Val Asp Pro Pro
Val His Ala Thr
Val His Thr Ala
Val Pro Asp Pro
Val Pro Pro Asp
Val Thr Ala His
Val Thr His Ala
Win 55212-2
C27H26N2O3 (426.19433260000005)
A organic heterotricyclic compound that is 5-methyl-3-(morpholin-4-ylmethyl)-2,3-dihydro[1,4]oxazino[2,3,4-hi]indole substituted at position 6 by a 1-naphthylcarbonyl group. D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002491 - Central Nervous System Agents > D000700 - Analgesics D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators
Methylcarbamyl PAF C-8
C18H39N2O7P (426.24947540000005)
Phe Gly Phe Gly
C22H26N4O5 (426.19031060000003)
Darifenacin
G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D000089162 - Genitourinary Agents > D064804 - Urological Agents Darifenacin(UK88525) is a selective M3 muscarinic receptor antagonist with pKi of 8.9. IC50 value: 8.9 (pKi) [1] Target: M3 receptor in vitro: Darifenacin exerts non-parallel rightward displacement of the agonist curve and also significant depression of the maximum response (+)-cis-Dioxolane produced concentration-dependent contraction of the isolated bladder of rat [1]. Darifenacin produces a concentration dependent increase in R123 (P-gp probe) accumulation in MDCK cells. Darifenacin stimulates ATPase activity in P-gp membrane in a clear concentration dependent response manner with an estimated ED50 value of 1.6 μM. Darifenacin (100 nM) shows a significantly greater permeability for darifenacin in the basolateral to apical direction resulting in an efflux ratio in BBMEC monolayers of approximately 2.6 [2]. in vivo: Darifenacin produces dose-dependent inhibition of amplitude of volume-induced bladder contractions(VIBCAMP), producing 35\% inhibition at dose of 283.3 nmol/kg and maximal inhibition of approximately 50–55\% [1]. Darifenacin (0.1 mg/kg i.v.) reduces bladder afferent activity in both Aδ and C fibers in female Sprague-Dawley rats, the decrease in afferent spikes in C fibers may be more pronounced than that in Aδ fibers [3].
Cinnzeylanine
2-eicosa-15S-hydroxy-5Z,8Z,11Z,13E,17Z-pentaenoylphloroglucinol
10,15-Dihydro-5,5,10,10,15,15-hexamethyl-5H-tribenzo[a,f,k]trindene
Nickel,bis(2,2,6,6-tetramethyl-3,5-heptanedionato-kO3,kO5)-, (SP-4-1)-
C22H40NiO4 (426.22799100000003)
H-D-Val-Leu-Lys-chloromethylketone trifluoroacetate salt
C18H36Cl2N4O3 (426.21643259999996)
Mehtyl 6-[3-(1-adamanty)-4-methoxy phenyl]-2-naphthoate
BIS(N,N,NN-TETRAMETHYL-D-TARTRAMIDEGLYCOLATO)DIBORON
2-acetamido-3-o-benzyl-4,6-o-benzylidene-2-deoxy-beta-d-glucopyranosyl azide
C22H26N4O5 (426.19031060000003)
Teneligliptin
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
(3S,4S)-TERT-BUTYL 3-(BENZYL((BENZYLOXY)CARBONYL)AMINO)-4-HYDROXYPYRROLIDINE-1-CARBOXYLATE
1,3-diisocyanato-2-methylbenzene,2-ethyl-2-(hydroxymethyl)propane-1,3-diol,hexane-1,6-diol
DU-14
C22H38N2O4S (426.25521480000003)
Teneligliptin (2R,4R)-Isomer
[(2S,4R)-4-[4-(3-Methyl-1-phenyl-1H-pyrazol-5-yl)-1-piperazinyl]-2-pyrrolidinyl]-3-thiazolidinylmethanone
Ripisartan
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist
n-3-(triethoxysilylpropyl)-n-3-(trimethoxysilyl-propyl)urea
BIS(N,N,NN-TETRAMETHYL-L-TARTRAMIDEGLYCOLATO)DIBORON
Methanesulfonamide, N-(3-(3-((2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl)-6-ethyl-3-azabicyclo(3.1.0)hex-6-yl)phenyl)-
C24H30N2O3S (426.19770300000005)
Pratosartan
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist
Methanone, (2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo(1,2,3-de)-1,4-benzoxazin-6-yl)-1-naphthalenyl-, (S)-
C27H26N2O3 (426.19433260000005)
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002491 - Central Nervous System Agents > D000700 - Analgesics D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators
L-Asparaginyl-L-phenylalanyl-L-phenylalanine
C22H26N4O5 (426.19031060000003)
Iloperidone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics Iloperidone (HP 873) is a D2/5-HT2 receptor antagonist. Iloperidone is an atypical antipsychotic for the schizophrenia symptoms[1][2].
oxatomide
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AE - Piperazine derivatives D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents D018926 - Anti-Allergic Agents Oxatomide is a potent and orally active dual H1-histamine receptor and P2X7 receptor antagonist with antihistamine and anti-allergic activity. Oxatomide almost completely blocks the ATP-induced current in human P2X7 receptors (IC50 of 0.95 μM). Oxatomide inhibits ATP-induced Ca2+ influx with an IC50 value of 0.43 μM and also inhibits serotonin[1][2].
8-(2,4-Dihydroxy-6-pentylphenoxy)-6-hydroxy-3-pentylisochromen-1-one
(1S,12R,23R)-12-methyl-23-(2-methylbut-3-en-2-yl)-3,11,14,16-tetrazahexacyclo[12.10.0.02,11.04,9.015,23.017,22]tetracosa-2,4,6,8,17,19,21-heptaene-10,13-dione
methyl (1R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
(3S,3aR,4S,6S,7R,7aR)-6-ethenyl-4-hydroxy-3,6-dimethyl-7-[(E)-1-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyprop-1-en-2-yl]-3,3a,4,5,7,7a-hexahydro-1H-inden-2-one
Asp-Val-Pro-Pro
A tetrapeptide composed of L-aspartic acid, L-valine and two L-proline units joined in sequence by peptide linkages.
N-[1-[(cyclohexylamino)-oxomethyl]cyclohexyl]-N-(thiophen-2-ylmethyl)-2-pyrazinecarboxamide
N-[3-(diethylamino)propyl]-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide
C21H30N8O2 (426.24915999999996)
1-[[4-Anilino-6-(1-piperidinyl)-1,3,5-triazin-2-yl]amino]-3-cyclohexylthiourea
1-[3-(dimethylamino)propyl]-3-(4-fluorophenyl)-1-[(6-methoxy-2-oxo-1H-quinolin-3-yl)methyl]urea
N-[2-(cyclohexylamino)-2-oxoethyl]-N-(5-methyl-3-isoxazolyl)-N-phenylpentanediamide
8-methyl-4-oxo-N-[3-(4-propyl-1-piperazinyl)propyl]-5H-thieno[3,2-c]quinoline-2-carboxamide
(3aS,5S,9aS)-2-[(2-methylphenyl)methyl]-5-(1-methyl-3-phenyl-4-pyrazolyl)-3a,4,5,7,8,9-hexahydro-3H-pyrrolo[3,4-h]pyrrolizin-1-one
2-[(1S,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide
1,2-Dipentanoyl-sn-glycero-3-phosphocholine
C18H37NO8P+ (426.22566720000003)
2-Nonadioyl-sn-glycero-3-phosphocholine
C17H33NO9P- (426.18928380000006)
(4R)-2-[4-(3-hydroxypropoxy)phenyl]-N-(3-methoxypropyl)-4-(phenylmethyl)-5H-oxazole-4-carboxamide
3-[3-[4-[Hydroxy(diphenyl)methyl]-1-piperidinyl]propoxy]benzonitrile
(1S,5R)-3-[(3,5-dimethoxyphenyl)methyl]-7-[4-[(E)-2-phenylethenyl]phenyl]-3,6-diazabicyclo[3.1.1]heptane
2-[(1S,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide
2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide
1-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
1-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
1-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
2-[(1R,3R,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide
2-[(1R,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide
2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide
2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide
2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide
[(2S,3R)-6-(benzenesulfonyl)-1-(cyclopentylmethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-2-yl]methanol
C24H30N2O3S (426.19770300000005)
1-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
1-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
1-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
1-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-phenylurea
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide
2-[(1R,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide
2-[(1S,3S,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide
2-[(1R,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide
2-[(1S,3R,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide
2-[(1S,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide
2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide
2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide
2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide
2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide
N,N-dimethyl-4-[4-[(1R,5S)-3-[oxo(2-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzamide
[(2S,3S)-6-(benzenesulfonyl)-1-(cyclopentylmethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-2-yl]methanol
C24H30N2O3S (426.19770300000005)
[(2R,3R)-6-(benzenesulfonyl)-1-(cyclopentylmethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-2-yl]methanol
C24H30N2O3S (426.19770300000005)
1-(4-Azidobenzyl)-4-[2-(diphenylmethoxy)ethyl]piperidine
3-(4-hydroxyphenyl)-1-[2,4,6-trihydroxy-3-[(2Z)-3-(hydroxymethyl)-7-methylocta-2,6-dienyl]phenyl]propan-1-one
2-[(3S)-3-benzylpiperazin-1-yl]-4-(4-imidazol-1-ylphenoxy)-5-methylpyrimidine
2,3-dihydroxypropyl [2-hydroxy-3-[(Z)-tridec-9-enoxy]propyl] hydrogen phosphate
2-[2,3-Di(pentanoyloxy)propoxy-hydroxyphosphoryl]oxyethyl-trimethylazanium
C18H37NO8P+ (426.22566720000003)
2(Isobutylmethyl(2-naphthylsilyl))-1-(trimethylsilyl)naphthalene
C28H34Si2 (426.21989240000005)
2-[(3-Acetyloxy-2-octanoyloxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
C18H37NO8P+ (426.22566720000003)
2-[(3-Butanoyloxy-2-hexanoyloxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
C18H37NO8P+ (426.22566720000003)
2-[(2-Heptanoyloxy-3-propanoyloxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
C18H37NO8P+ (426.22566720000003)
9-Hydroxy-risperidone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
(±)-Darifenacin
(±)-Darifenacin is the racemate of Darifenacin. Darifenacin is a selective M3 muscarinic receptor antagonist[1].
Etrumadenant
Etrumadenant (AB928) is an orally bioavailable, selective dual adenosine receptor (A2aR/A2bR) antagonist. Etrumadenant relieves adenosine-mediated immune suppression. Etrumadenant has immunomodulatory and antitumor activities[1][2].
His-[D-2-ME-Trp]-Ala
C21H26N6O4 (426.20154360000004)
His-[D-2-ME-Trp]-Ala is a fragment of the growth hormone hexarelin.
SB269652
SB269652 is the first drug-like allosteric modulator of the dopamine D2 receptor (D2R); a new chemical probe that can differentiate D2R monomers from dimers or oligomers depending on the observed pharmacology. IC50 value: 0.2/0.5 nM [1] Target: D3 receptor antagonist SB269,652 potently (low nanomolar range) abolished specific binding of [(3)H]nemanopride and [(3)H]spiperone to Chinese hamster ovary-transfected D(3) receptors when radioligands were used at 0.2 and 0.5 nM, respectively. However, even at high concentrations (5 μM), SB269,652 only submaximally inhibited the specific binding of these radioligands when they were employed at 10-fold higher concentrations. By analogy, although SB269,652 potently blocked D(3) receptor-mediated activation of Gα(i3) and phosphorylation of extracellular-signal-regulated kinase (ERK)1/2, when concentrations of dopamine were increased by 10-fold, from 1 μM to 10 μM, SB269,652 only submaximally inhibited dopamine-induced stimulation of Gα(i3) [1].
7,8-diformyl-4a-hydroxy-4,4,8a-trimethyl-2,3,5,8-tetrahydro-1h-naphthalen-1-yl 3-(4-methoxyphenyl)prop-2-enoate
(1s,2r,3r,4r,7s,8z,12s,13s,14s,17s)-3,12,14,17-tetrahydroxy-4,9,13,17-tetramethyl-5-oxo-6-oxatricyclo[11.4.0.0³,⁷]heptadec-8-en-2-yl acetate
2-(3,3-dimethylbutyl)-1,3,6-trihydroxy-7-methoxy-8-(3-methylbut-2-en-1-yl)xanthen-9-one
methyl (1s,9s,10r,12s,13e,18r)-18-[(acetyloxy)methyl]-13-ethylidene-10-hydroxy-8-methyl-8,15-diazapentacyclo[10.5.1.0¹,⁹.0²,⁷.0⁹,¹⁵]octadeca-2,4,6-triene-18-carboxylate
(1s,2r,5s,6s,7s,9r)-5-(acetyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl (2e)-3-phenylprop-2-enoate
(7r)-7-[(1e,3e,5e,7e)-8-[(2s,3r,6s)-3-hydroxy-3,5,6-trimethyl-2,6-dihydropyran-2-yl]nona-1,3,5,7-tetraen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione
7-[8-(3-hydroxy-3,5,6-trimethyl-2,6-dihydropyran-2-yl)nona-1,3,5,7-tetraen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione
2,18-dimethyl 4-methoxy-2,12-diazahexacyclo[14.2.2.1⁹,¹².0¹,⁹.0³,⁸.0¹⁶,²¹]henicosa-3,5,7-triene-2,18-dicarboxylate
2-[(4-methylpentyl)oxy]-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol
(1s,5s,10r)-5-(3,4-dihydroxyphenyl)-9-hydroxy-13,13-dimethyl-2-(3-methylbut-2-en-1-yl)-4,14-dioxatricyclo[8.4.0.0³,⁸]tetradeca-2,8-dien-7-one
5,5'-diisopropyl-3,3',8,8'-tetramethyl-[2,2'-binaphthalene]-1,1'-diol
(1s,4r,10s,11s,15s)-5,5,10,13,15-pentamethyl-6,19,22-trioxahexacyclo[13.7.1.0¹,¹¹.0⁴,¹⁰.0¹³,²¹.0¹⁷,²¹]tricosa-8,16-diene-7,14,18-trione
(1r,4ar,8r,8as)-7,8-diformyl-4a-hydroxy-4,4,8a-trimethyl-2,3,5,8-tetrahydro-1h-naphthalen-1-yl (2e)-3-(4-methoxyphenyl)prop-2-enoate
4-[(1s,3ar,4s,6ar)-4-{3-methoxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl}-hexahydrofuro[3,4-c]furan-1-yl]-2-methoxyphenol
(1s,1's,2's,5's,9's,10'r,13'r,14's)-5',10',14'-trimethyl-6',16'-dioxaspiro[cyclohexane-1,7'-pentacyclo[12.3.3.0¹,¹³.0²,¹⁰.0⁵,⁹]icosan]-3-ene-2,5,15'-trione
(1r,2s,3s,5s,6s,8s,9s,10s,11r,15s,16r)-3,9,10,15-tetrahydroxy-16-methoxy-6-(methoxymethyl)-12,12-dimethyl-17-oxapentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecan-7-one
methyl 11-(acetyloxy)-12-ethyl-10-hydroxy-8-methyl-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6,13-tetraene-10-carboxylate
(2s,3r)-5-hydroxy-2-(2-hydroxypropan-2-yl)-3-[(3s)-3-(2-hydroxypropan-2-yl)-7-methyl-2,3-dihydro-1,4-benzodioxin-5-yl]-2,3-dihydro-1h-indene-4-carbaldehyde
3-(3-hydroxy-1,4-dioxonaphthalen-2-yl)-2,2-dimethylpropyl 5-(2,3-dimethyloxiran-2-yl)-2-methylpent-2-enoate
8-[2-(furan-3-yl)-2-hydroxyethyl]-3,4,5-trihydroxy-4-(hydroxymethyl)-4a,7,8-trimethyl-hexahydro-1h-naphthalen-1-yl acetate
(1s,4s,7s,9r)-16-acetyl-7-hydroxy-9-(2-methylbut-3-en-2-yl)-4-(2-methylpropyl)-5-oxa-2,16-diazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-10,12,14-triene-3,6-dione
7-[8-(5-hydroxy-3,5,6-trimethyl-2,6-dihydropyran-2-yl)nona-1,3,5,7-tetraen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione
(1r,3r,4s,9s,16s,18s,19r,21s)-16-(hydroxymethyl)-13-methoxy-12,20-dimethyl-11,14-dioxo-5-oxa-8,17,20-triazahexacyclo[15.3.1.0³,¹⁹.0⁴,⁸.0⁹,¹⁸.0¹⁰,¹⁵]henicosa-10(15),12-diene-21-carbonitrile
C22H26N4O5 (426.19031060000003)